Attovia Therapeutics, Inc. Common Stock Asset Resilience Ratio
Attovia Therapeutics, Inc. Common Stock asset resilience ratio. Attovia Therapeutics, Inc. Common Stock (ATTO) has an Asset Resilience Ratio of 64.12% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Attovia Therapeutics, Inc. Common Stock liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Attovia Therapeutics, Inc. Common Stock (2024–2025)
Asset resilience ratio of Attovia Therapeutics, Inc. Common Stock from 2024 to 2025. This chart shows how Attovia Therapeutics, Inc. Common Stock's Asset Resilience Ratio has changed over time. Read ATTO total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Attovia Therapeutics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ATTO asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $82.30 Million | 64.12% |
| Total Liquid Assets | $82.30 Million | 64.12% |
Asset Resilience Insights
- Very High Liquidity: Attovia Therapeutics, Inc. Common Stock maintains exceptional liquid asset reserves at 64.12% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Attovia Therapeutics, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Attovia Therapeutics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Attovia Therapeutics, Inc. Common Stock Asset Resilience Ratio by Year (2024–2025)
Attovia Therapeutics, Inc. Common Stock asset resilience ratio by year from 2024 to 2025. The table below shows the annual Asset Resilience Ratio data for Attovia Therapeutics, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 67.56% | $112.08 Million | $165.89 Million | +17.12pp |
| 2024-12-31 | 50.43% | $38.69 Million | $76.72 Million | -- |
About Attovia Therapeutics, Inc. Common Stock
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of… Read more